Melanoma

Unresectable
Stage III-IV

Any Line

1st Line

BRAF +

Receiving Palliative Radiation

Prior Brain Metastasis

Melanoma

Ocular Melanoma

Resected
Adjuvant Therapy
Stage III-IV

Requires Injectable Lesions

MEL0006
Phase III
(Atezolizumab
vs Placebo) +
Cobimetinib &
Vemurafenib in
Metastatic
Melanoma

PI: Reddy
(Pending)

MEL0015
Phase I
Ipilimumab &
Nivolumab
(Blockade) +
External Beam
Radiotherapy in
Stage IV
Melanoma

PI: Knox
Ludwig Institute for
Cancer Research

BRN0027
Phase II in
Metastatic Brain
Melanoma
Progressed / Relapsed on
PD-1 Inhibitor Tx

PI: Reddy
Delcath Systems

MEL0017
Phase II
Nivolumab +/-
Ipilimumab in
Stage III-IV
Melanoma

PI: Reddy
(Pending)

ECOG-ACRIN-S1404
Phase III High Dose Interferon or Ipilimumab vs MK-3475(Pembrolizumab) in High Risk Resected Melanoma

PI: Reddy
ECOG-ACRIN

MEL0018
Phase II
IMCgp100 vs Investigator Choice in HLA-A*0201 Positive Untreated Advanced Uveal Melanoma

PI: Reddy
(Pending)

SKIN0036
Phase II
Melphalan/HDS Treatment in Hepatic-Dominant Ocular Melanoma

PI: Reddy
Delcath Systems

†

MELMTS0007
Phase IIa
OBP-301 Telomerase Specific Replication-Competent Oncolytic Adenovirus in Mets Melanoma

PI: Reddy
(Pending)

ECOG-ACRIN-CA6141
Phase II/III
Nivolumab&Ipilimumab +/- Sargramostim in Unresectable Unresectable Stage III/IV Melanoma

PI: Reddy
ECOG-ACRIN

METS0003
Phase Ib/II
Intratumoral SD-101 +Pembrolizumab in Metastatic Melanoma or Recurrent / Metastatic HNSCC

PI: Kumar
Dynavax Technologies Corporation

MELMTS0006
Phase I
Dose Escalation Study of Cabozan in Metastatic Melanoma

PI: Reddy
ECOG-ACRIN

KEY

- - - Optional Path

Pending

Open for Enrollment

Link Trial Posting

Extension Study

Immunotherapy

Observational Study

Enrollment on Hold